Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Not Adequately Controlled by Their Lipid-Modifying Therapy

Next Previous
X
Search
Trial Profile

A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Not Adequately Controlled by Their Lipid-Modifying Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Atherosclerosis; Hyperlipoproteinaemia type IIa
  • Focus Registrational; Therapeutic Use
  • Acronyms CLEAR Wisdom
  • Sponsors Esperion Therapeutics

    • Most Recent Events

    • 01 Nov 2023 Results assessing the effect of bempedoic acid in women and men using pooled, patient-level data from four phase 3 clinical trials of bempedoic acid (CLEAR Wisdom (NCT02991118), CLEAR Harmony (NCT02666664), CLEAR Tranquility (NCT03001076), and CLEAR Serenity (NCT02988115)) published in the Atherosclerosis.
    • 18 Apr 2022 Results of post-hoc pooled analysis of four studiesCLEAR Tranquility; NCT03001076), (CLEAR Serenity; NCT02988115), (CLEAR Wisdom [NCT02991118] and CLEAR Harmony [NCT02666664]) assessing effect of bempedoic acid on glycaemic and lipid variables in patients with hypercholesterolaemia, published in the Diabetes, Obesity and Metabolism.
    • 12 Nov 2021 According to an Esperion Therapeutics media release, results of pooled efficacy analysis from the four Phase 3 clinical studies of NEXLETOL presented at the American Heart Association (AHA) Scientific Sessions 2021 taking place on November 13-15, 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top